For personal use only - Australian Securities Exchange

For personal use only
ASX ANNOUNCEMENT
15 January 2015
TOP 20 SHAREHOLDERS
Rank
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
Holder Name
CELTIC CAPITAL PTE LTD <TRADING 1 A/C>
PROFESSOR IGOR SLUKVIN
MR IAN DIXON
EQUITAS NOMINEES PTY LTD <GROUP A A/C>
TISIA NOMINEES PTY LTD <HENDERSON FAMILY A/C>
DR ALLEN BOLLANDS
DR ROGER ASTON
JOHN W KING NOMINEES PTY LTD
JK NOMINEES PTY LTD<THE JK FUND A/C>
DENLIN NOMINEES PTY LTD
ARDROY SECURITIES PTY LTD <CAMERON INVESTMENT UNIT A/C>
WEBINVEST PTY LTD <OSLB UNIT A/C>
BANNABY INVESTMENTS PTY LTD <BANNABY SUPER FUND A/C>
DR MAKYSM VODYANYK
INTERSUISSE NOMINEES PTY LTD <CUSTODIAN A/C>
MR GREGORY PINKUS & MRS LISA PINKUS <PINKUS FAMILY SUPER
FUND A/C>
MR GRANT PATERSON <GTP FAMILY A/C>
MR PETER CAPP <CAPP FAMILY A/C>
CM COOK SUPERANNUATION PTY LTD
AVIEMORE CAPITAL PTY LTD
Shares
%
2,650,000
2,383,317
2,383,317
1,937,300
1,920,059
1,787,488
1,787,488
1,780,000
1,750,000
1,646,916
1,470,211
1,325,000
1,293,916
1,191,658
1,181,257
4.01%
3.61%
3.61%
2.93%
2.91%
2.71%
2.71%
2.69%
2.65%
2.49%
2.23%
2.01%
1.96%
1.80%
1.79%
850,000
793,916
700,000
700,000
689,046
1.29%
1.20%
1.06%
1.06%
1.04%
30,220,889
45.76%
Media contacts: Dr Ross Macdonald, CEO: Tel: 0412 119343; email [email protected]
Dr Stewart Washer, Executive Chairman: Tel: 0418 288212; email [email protected]
About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a
therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world
leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing
methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic
manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor,
called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of
donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a
pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent
arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.
Cynata Therapeutics Limited – Suite 1, 1233 High Street, Armadale, Victoria 3143 - PO Box 7165,
Hawthorn North, Victoria 3122 T: + 613 9824 5254 F: + 613 9822 7735 E: [email protected]
W: www.cynata.com ABN - 98 104 037 372

Download Report